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INTRODUCTION  
A sustained-release dosage form is defined as “any drug 
or dosage form modification that prolongs the 
therapeutic activity of the drug”1. Development of oral 
sustained release (SR) tablets of highly water soluble 
drugs or bioactives has always been a challenge and 
therefore, opportunity for formulation scientist. Most of 
these drugs if not formulated properly, may be released 
at a faster rate resulting in exceeding the maximum 
therapeutic levels and hence will lead to toxic side 
effects. Sustained delivery of such drugs ensures 
improved drug delivery and patient compliance, greater 
safety and efficacy, desired release kinetics and helps in 
maintaining the plasma drug concentration within the 
therapeutic window for extended period of time2,3. 
Lipids (such as Compritol ATO 888) are considered as 
an alternative to polymer in the design of sustained drug 
delivery systems due to their advantages such as the low 
melt viscosity (thus avoiding the need of organic 
solvents for solubilization), absence of toxic impurities 
such as residual monomer catalysis and initiators, 
potential biocompatibility and biodegradability4. 
However, research data obtained by experiments suggest 
that Compritol ATO 888 may be recommended as a 
matrix agent in the development of sustained release 
formulation in spite of its traditional role as a lubricant. 
Lipids like glycerides are a family of excipients which 
have generated considerable interest in the preparation of 
oral dosage forms. Some glycerides such as Compritol 
ATO 888 (glyceryl behenate), Precirol ATO 5 (glyceryl 
palmitostearate) can be used for the preparation of 
sustained release dosage forms5. The esterification of 
glycerol by long chain fatty acid gives them a 
pronounced hydrophobic character with a low HLB 
value of 2 6. Several techniques including melt 
granulation 7, melt pelletization 8, hot melt extrusion 9 
and hot melt coating 10 have been used to obtain 
sustained release dosage forms from glycerides-based 
formulations. 
Melt granulation (MG) is a solvent-free process which 
involves the use of a substance that melts at a relatively 
low temperature. This substance can be added in the 
molten form over the substrate or in the solid form, 
which is then heated above its melting point. The 
substance acts as a liquid binding agent, and the 
technique does not require the use of organic solvents. 
Moreover, in melt granulation drying is not necessary 
and thus, the process is less consuming in terms of time 
and energy compared to other methods 4. Sustained 
release matrix tablets have been produced with 
Compritol ATO 888 by various methods including MG 
11, wet granulation (WG) and direct compression (DC) 12. 
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ABSTRACT 
Objective: The objective of this work was to prepare and evaluate oral sustained release matrix tablet of highly water soluble 
drug and to study the effect of proportion of wax and addition of release liner on in-vitro release of drug. 
Method: The matrix tablets were prepared by melt granulation method using drug:wax in 1:1, 1:2 & 1:3 proportions and 
evaluated for on in-vitro drug release. Then the proportion 1:1 was selected and wax matrix tablets were prepared by three 
techniques melt granulation, wet granulation and direct compression to check their in-vitro release profiles. 
Results: The study revealed that Compritol ATO 888 is potent sustained release polymer and released only 72.45% in 24 h 
even at 1:1 proportion. So, lactose was added as release liner in further study which helped in achieving complete release in 
24h. 
Conclusion: The present study has concluded that Compritol ATO 888 can be used as matrix-forming agent to control the 
release of a highly water soluble drug such as Eperisone HCl. It was also observed that melt granulation technique was found 
more effective. Release liner like lactose may help enhancing the release profile when it is marginally slow. 
Keywords: - Eperisone Hydrochloride, Compritol ATO 888, Sustained release, Melt granulation, Release liner 
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Eperisone Hydrochloride, an established Muscle relaxant 
acts by relaxing both skeletal muscles and vascular 
smooth muscles and demonstrates reduction of myotonia, 
improvement of circulation, and suppression of pain 
reflex in case of Spastic paralysis, Neck-shoulder-arm 
syndrome, scapulohumeral periarthritis and low back 
pain. The melting point of Compritol ATO 888 and 
Eperisone hydrochloride is 65-77 and 167°C, 
respectively. Therefore, it is a thermally stable drug and 
MG technique should not affect the thermal stability of 
the drug. It has a plasma elimination half-life of 1.6-1.87 
h with a usual dosage regimen of 50 mg trice daily. 
Therefore, to reduce frequency of administration and 
improve patient compliance, a sustained release dosage 
formulation of Eperisone Hydrochloride is desirable. The 
drug is associated with certain side effects such as Shock 
and anaphylactoid reactions like redness, itching, 
urticaria and Toxic epidermal necrolysis. Therefore, a 
properly designed sustained release dosage form of the 
drug should also minimize fluctuation in blood 
concentration, reduced risk of side effects and show 
uniform pharmacological response 13-15. 
Sustained release matrix tablets of Eperisone 
Hydrochloride have previously been produced using 
hydrophilic polymers like HPMC, HPC 16 The objective 
of the present study was to prepare oral sustained release 
matrix tablet of a highly water soluble drug by MG using 
Compritol ATO 888, and to evaluate the effect of the 
concentration of the lipid and presence of release liner on 
the release of the drug. Such a sustained release 
formulation, if achieved, would be substantially more 
affordable than those previously developed. 
METHODS 
Materials 
Eperisone Hydrochloride was a gift from Sharon Bio-
Medicine, Mumbai, India while Compritol ATO 888 was 
obtained free of charge from Gattefosse SAS India. Di-
Calcium phosphate, magnesium stearate, lactose, Aerosil 
200, isopropyl alcohol, concentrated hydrochloric acid, 
sodium hydroxide and potassium dihydrogen phosphate 
were purchased from SD Fine chemicals, Mumbai, India. 
Double distilled water (D.W.) was prepared freshly 
whenever required. Other chemicals and reagents used 
were of analytical grade. 
Methods  
Preparation of Eperisone hydrochloride matrix tablets 
Preparation of wax matrix tablets was done by three 
methods: MG, WG and DC as follows. 
Melt granulation method: The wax(Compritol 888 ATO) 
was melted in a porcelain dish over a water bath 
maintained at 75-80°C for 3 min and Eperisone 
Hydrochloride was gradually added with continuous 
stirring until uniformly mixed. The molten mixture was 
allowed to cool and solidify at room temperature crushed 
in a mortar and passed through a 40# sieve. The granules 
were compressed into flat–faced tablet using multi-
station rotary tablet compression machine (Karnavati 
engineering Pvt. Ltd. India) at a constant compression 
force. 
Wet granulation method: Drug & excipients (except 
magnesium stearate) were blended geometrically in a 
mortar and pestle for 15 minutes then wet granulation 
was performed by addition of IPA in sufficient quantity. 
dough mass was passed through 16# sieve (ASTM) and 
dried at 35-40°C for 15 min. dried granules were passed 
from 40# sieve and compressed into tablets using multi-
station rotary tablet compression machine. 
Direct Compression method: All the ingredients were 
passed from 60# sieve (ASTM) and directly compressed 
into tablet using multi-station rotary tablet compression 
machine. 
Evaluation of drug - Excipient interaction: The pure 
drug, wax and the matrix tablet formulation were 
subjected to IR spectroscopy using FT-IR 
spectrophotometer (Shimadzu – 8400, Japan). Their 
spectra were obtained over the wave number range of 
4000 – 400 cm-1. 
In-vitro drug release: In vitro release studies were 
conducted using USP type II paddle apparatus (VDA-6D 
USP Std -VEEGO) run at 50 rpm. The buffer was kept at 
thermostatically controlled temperature of 37±0.5°C. The 
test was carried out in 900 ml of 0.1 M HCl for 2 h and 
then replaced with phosphate buffer (pH 6.8) as the 
dissolution medium for another 22 h. The pH change of 
medium was effected by adding 4.32 g of sodium 
hydroxide and 6.08 g of potassium dihydrogen phosphate 
dissolved in 5 ml water to the previous acidic medium 
(0.1 M HCl) 17. Five milliliters samples were withdrawn 
at the time intervals of 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 
and 24 h and replaced with equal volume of fresh 
dissolution medium. The samples were filtered through 
0.45 µm filter and analyzed for drug content at 260 nm 
by UV spectrophotometer. 
The release profile of prepared tablets was matched with 
the set values of drug release at different time points, 
mentioned below 
Initial 2 h  20-30% 
At 8th h   50-60% 
At 14
th
 h   70-80% 
At 20th h   NLT 85% 
Drug release kinetics: To determine the mechanism of 
drug release from the formulations, the data were 
subjected to zero-order (Eq 1), first order (Eq 2) and 
Highuchi (Eq 3) release kinetics 18, 19 
Mt = M0 + k0t ……………………….   (1) 
In Mt = In M0 + k1t …………………   (2) 
Mt = M0 + kHt
1/2
 ……………...……...  (3) 
where Mt is the cumulative amount of drug released at 
any time, t, and M0 is the dose of the drug incorporated 
in the delivery system. k0, k1 and kH are rate constants for 
zero-order, first order and Higuchi models, respectively. 
The dissolution data were also fitted according to the 
well-known exponential equation of Peppas 20, as in Eq 
4, which is often used to describe drug release behavior 
from polymeric systems. 
    Mt/M∞ = kt
n…………………….... (4) 
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Where, Mt/M∞ is the fraction of drug released at time t, k 
is the kinetic constant, and n is the diffusional exponent 
for drug release. The diffusion exponent, n, is dependent 
on the geometry of the device as well as the physical 
mechanism of release. Zero order release describes a 
release rate independent of drug concentration while the 
Higuchi square root kinetic model describes a time 
dependent release process. The value of n indicates the 
drug release mechanism; if 0.1 < n < 0.5, Fickian 
diffusion is indicated while 0.5 < n < 1 indicates non-
Fickian diffusion. 
Mean dissolution time: MDT is the mean time for the 
drug to dissolve under in vitro dissolution conditions. 
MDTin-vitro=
  tmid  ΔMni=1
   ΔMni=1
  ……………. (5) 
Where, 
i = the sample number, n is the number of dissolution 
samples, 
tmid = the time at the midpoint between i and i – 1,  
M = the additional amount of drug dissolved between i 
and i-1  
MDT value is used to characterize the drug release rate 
from the dosage form and the retarding effect of the 
polymer. As it is readily apparent, the higher the polymer 
level, the higher the value of MDT and the greater the 
retarding effect of the polymer (21). 
Area under cure: AUC is the area under the 
curve (mathematically known as integral) in a plot of 
concentration of drug in blood plasma against time. The 
AUC (from zero to infinity) represents the total drug 
exposure over time. Assuming linear pharmacodynamics 
with elimination rate constant K, one can show that AUC 
is proportional to the total amount of drug absorbed by 
the body (i.e. the total amount of drug that reaches the 
blood circulation). The proportionality constant is 1/K. 
In present study, AUC is calculated for in vitro drug 
release by plotting graph of %CDR versus time using Eq. 
(6)  
(AUC)0
t =   
Cn +Cn +1
2
 
t
0
X (tn − tn−1)   
…………………. (6) 
                    Where, 
 C   = % cumulative drug release, 
 t     = time point,  
AUC was used for the optimization purpose here. % 
difference in AUC values can give idea about 
comparative drug release amount in 24h. It was applied 
when other statistical parameters were giving similar 
results. Here, profiles showing 10% difference in AUC 
were considered as dissimilar. 
RESULTS AND DISCUSSION 
Interaction between drug and wax was checked by FT-IR 
Spectroscopy. As shown in Figure 1, the major IR peaks 
observed in the spectra for tablet formulation were, the 
sharp absorption band of the conjugation carbonyl group 
around 1674 (C=O) and 1604 cm−1 (C=C), -N-H stretch 
at 1566cm-1, C-H bend at 1465cm-1, which are 
characteristic of Eperisone Hydrochloride. When this is 
compared to the spectra of the formulations, it would 
appear that there was no obvious interaction between 
drug and the Compritol ATO 888.  
 
 
Figure 1: FTIR spectra of Eperisone hydrochloride (A), Compritol ATO 888 (B) and tablet formulation containing all 
the Ingredient (C). 
 
Wax matrix tablet of Eperisone Hydrochloride was prepared by MG in three different proportion (1:1, 1:2, & 1:3) and 
effect of proportion of wax matrix on in-vitro release profile of drug was studied.   
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Table 1: Composition of Eperisone Hydrochloride matrix tablets 
Ingredients F1
a
 F2
 a
 F3
 a
 F4
 a
 F5
 b
 F6
 c
 
Eperisone Hydrochloride 150 150 150 150 150 150 
Compritol 888 ATO 150 300 450 150 150 150 
Lactose    30 30 30 
Polyvinyl pyrrolidone K30    15 15 15 
Di-Calcium Phosphate    12 12 12 
Magnesium Stearate    3 3 3 
Total 300 450 600 360 360 360 
* All amount in mg/tablet 
To keep the formulation uniform, ingredients required to be added in WG & DC have also been added in MG in F4. 
a -Tablets prepared using melt granulation. 
b -Tablets prepared using wet granulation. 
c -Tablets prepared using direct compression  
In-vitro release study revealed that the drug was 
72.45±2.9, 56.43±2.3, and 41.66±2.0% cumulative drug 
release at the end of 24 h for formulations F1, F2, and 
F3, respectively. Thus, indicating that drug release fell as 
the wax content of the tablets increased. The difference 
in release rate between the batches was statistically 
significant (Similarity factor f2 values were 46.86 and 
32.55 respectively for F2 and F3 with that of F1). 
 
Figure 2: Effect of different concentration of Compritol 
ATO 888 on in-vitro release of formulation of eperisone 
hydrochloride matrix tablets. 
 
As the study aimed to develop 24 h release profile, none 
of the above fits completely. But, with change in 
composition or change in the method, the goal may be 
achieved in 1:1 composition. Further batches were 
prepared by different techniques like WG, & DC. 
Addition of lactose was done as release liner along with 
other ingredient, keeping drug:wax proportion constant 
at 1:1.  
Optimized proportion was further compared with other 
methods like Wet granulation and direct compression 
along with addition of lactose as release liner. 
Comparison of the three methods of formulation used 
indicate that sustaining effect from the tablets prepared 
by Wet granulation (F5, 99.12% in 20h) and direct 
compression (F6, 99.25% in 16h) were significantly 
higher (p <0.05) than from the equivalent formulation 
made by melt granulation (F4, 98.62% in 24h)  
 
Figure 3: Comparative in-vitro Release profiles of 
sustained release matrix tablet made by MG (F4), WG 
(F5) and DC (F6), in the ratio of 1:1. 
 
Drug release kinetics: Table 2 shows that the best-fit 
release kinetic data with the highest values of regression 
coefficient (r2) were shown by Higuchi models and zero 
order. The values of n were in the range of 0.502 to 
0.693 (i.e., between 0.50 – 0.89) exhibits non-fickian 
(anomalous) transport in which the drug was delivered 
by combined effect of diffusion and polymer relaxation 
(21). Data of r2 indicate that Peppas models also suitably 
described the release of Eperisone hydrochloride from 
the matrix tablets. None of the formulation exhibited first 
order kinetics. 
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Table 2: In vitro release kinetics of Eperisone hydrochloride matrix tablets 
Formulation Code F1 F2 F3 F4 F5 F6 
Zero order 0.876 0.898 0.932 0.925 0.865 0.856 
Fist order 0.719 0.737 0.684 0.722 0.621 0.655 
Higuchi 0.991 0.996 0.994 0.997 0.983 0.980 
Peppas Model r2 0.99 0.994 0.979 0.991 0.945 0.956 
N 0.502 0.521 0.693 0.611 0.624 0.593 
K 16.26 11.46 5.28 15.35 18.37 22.80 
AUC 1237.31 935.24 654.27 1347.47 1602.97 1559.65 
MDT 15.11 22.34 35.9 8.19 5.83 4.42 
       
 
Influence of proportion of Wax on in-vitro drug 
Release.  
As shown in figure 2 as ratio of polymers increased from 
1:1 to 1:3, it resulted into greater retardation of drug 
release. This might be due to an increased polymer 
concentration resulting in a decrease in the total porosity 
of the matrices (initial porosity plus porosity due to 
dissolution of the drug), decreasing the penetration of the 
dissolution medium into the matrix system and thus 
reducing drug dissolution. In addition, increasing the 
polymer content led to an increase in the drug diffusion 
path length, which in turn retarded drug diffusion from 
the matrix 21. As stated earlier, based on kinetic analysis 
of release data, Eperisone hydrochloride release occurred 
by a non-Fickian diffusion mechanism. The initial drug 
release (i.e., in the 2 hour) of 23.80, 33.74, and 40.62% 
for F4, F5 and F6, respectively, may be attributed to 
„burst‟ release of the drug on the tablet surface 
irrespective to method of formulation. 
Influence of method of formulation on Release 
Influence of method of formulation on Release was also 
studied. Results obtained from DC and WG method 
indicated negligible role of binding agent in release 
retardation, thus suggesting use of MG as the most 
effective method in sustaining Eperisone hydrochloride 
release. Figure 3 shows release profile of Compritol 
ATO 888 in 1:1 ratios prepared by MG (F4), WG (F5) 
and DC (F6). These results are in accordance with 
previously published results. 12, 21 In case of MG, lesser 
drug release is occurring because of complete and proper 
coating of melted wax on drug particles which forms 
uniform hydrophobic wax matrix through the tablet. So, 
here penetration of dissolution medium to the matrix will 
be low hence dissolution occurs at slower rate. However, 
in case of matrices prepared by DC or WG, it seems that 
the dissolution of drug particle at surface of matrices 
allowed the establishment of channels through which 
drug was released.  
Relative retardation can be ranked depending upon 
method of formulation as – 
Melt granulation> Wet granulation> Direct compression 
 
Figure 4: Comparative in-vitro release profile of F1 and 
F4 to study influence of Lactose on release 
Influence of release liner on in-vitro drug Release. 
As shown in figure 4 addition of 10% lactose as release 
liner can give significant (26.17%) rise in release. F4 
gives high initial release as well as higher release of drug 
over the time range of experiment. However, release of 
both batches matches to zero order and higuchi kinetic 
data. Still MDT decreases from 15.11h to 8.19h at the 
same wax concentration as lactose was added. 
Thus, the effect of additives like lactose, MCC, DCP on 
release of drug from matrices has been well established 
and it is also known to control and differ the initial 
release & release over time period. In present research 
and Studies done before shows that by including water 
soluble diluents such as lactose, near zero order release 
also can be achieved from matrix system 12, 21. The 
overall mechanism of release of the drug from glyceryl 
behenate matrices appeared to be a diffusion-controlled 
mechanism. The data of drug release were fitted to the 
Higuchi's square root of time model. The mechanism of 
this evidence indicated that the prepared tablets behaved 
as inert matrices. Visual observation of the tablets during 
the dissolution studies revealed that the tablets remained 
intact without any significant change in their shape. 
These observations support our conclusion that the 
release of the drug is mainly due to diffusion through the 
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channels formed in the matrix. These channels are 
formed due to rapid dissolution of the drug particles on 
the surface of the matrix and the presence of the water-
soluble release enhancers like lactose. Then, the 
dissolution medium would penetrate these channels 
allowing for more dissolution of the drug present in the 
deeper sites of the matrix. 
It was observed that the values of AUC were higher 
when lactose was added in formulation F4 to F6. WG 
method was showing highest value of 1602.97 but, it 
could not retard the release upto 24 h. However, MG 
process was found to be best fitting to all other criteria 
with satisfactory AUC value of 1347.47 which was 
found best among all other formulations.  
CONCLUSION 
The study showed that Compritol ATO 888 is an 
appropriate waxy matrix former for sustained release of 
highly water-soluble drug such as eperisone 
hydrochloride. Drug release was diffusion-controlled 
(non-fickian) and achieves almost near to zero order in 
all the formulations. 
MG technique fits completely into the predetermined 
parameter and criteria whereas, other two techniques 
lack behind. Extended release profiles can be achieved 
by any of three methods using Compritol ATO 888 at 
higher proportion but MG technique achieved 24 h 
release profile with lesser amount of was as compare to 
other methods.  
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